Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

BACKGROUND: In Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies – a physician survey and a medical records review (MRR) – were conducted to evaluate the use of panitumumab and awareness among prescribi...

Descripción completa

Detalles Bibliográficos
Autores principales: Han van Krieken, J., Kafatos, George, Bennett, James, Mineur, Laurent, Tomášek, Jiří, Rouleau, Etienne, Fabian, Pavel, De Maglio, Giovanna, García-Alfonso, Pilar, Aprile, Giuseppe, Parkar, Parijan, Downey, Gerald, Demonty, Gaston, Trojan, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706421/
https://www.ncbi.nlm.nih.gov/pubmed/29183279
http://dx.doi.org/10.1186/s12885-017-3740-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706421/
https://www.ncbi.nlm.nih.gov/pubmed/29183279
http://dx.doi.org/10.1186/s12885-017-3740-4

Ejemplares similares